Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:40:18.960Z.
Calculation as of: 2026-10-06T22:40:18.960Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c6190991d8493eebdba731817b981db063e7ae28b86b69413d904cae69ffb2ef
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$48.76M
EV/EBITDA Ratio
N/A
TTM Avg
310.55x
3Y Avg
191.07x
5Y Avg
171.86x
Market Cap
$48.89M
EV/EBITDA Ratio
N/A
TTM Avg
10.84x
3Y Avg
9.14x
5Y Avg
10.29x
Market Cap
$49.25M
EV/EBITDA Ratio
N/A
TTM Avg
119.16x
3Y Avg
119.16x
5Y Avg
119.16x
Market Cap
$49.71M
EV/EBITDA Ratio
N/A
TTM Avg
35309.82x
3Y Avg
79402.66x
5Y Avg
79402.66x
Market Cap
$50.27M
EV/EBITDA Ratio
N/A
TTM Avg
335.70x
3Y Avg
335.70x
5Y Avg
335.70x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TELA Bio, Inc. (TELA) | $48.77M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $48.76M | N/A | 310.55x | 191.07x | 171.86x |
| Sensus Healthcare, Inc. (SRTS)vs › | $48.89M | N/A | 10.84x | 9.14x | 10.29x |
| Apollomics, Inc. (APLM)vs › | $48.53M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.25M | N/A | 119.16x | 119.16x | 119.16x |
| Clene Inc. (CLNN)vs › | $49.45M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $47.98M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $49.71M | N/A | 35309.82x | 79402.66x | 79402.66x |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | N/A | 335.70x | 335.70x | 335.70x |
| biote Corp. (BTMD)vs › | $50.28M | 9.02x | 5.34x | 6.36x | 5.55x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
